Presentations & Publications

Clinical

  • Pahwa R,  Hauser R, Oertel W, Trenkwalder C, Reinhard E,  Azulay JP, Isaacson S, Felt L, Ruby A, McClure N, Stempien, MJ. Results of a Phase 3 Efficacy and Safety Study of ADS-5102 (amantadine HCl) Extended-Release Capsules in Parkinson’s disease Patients with Levodopa-Induced Dyskinesia (EASE LID 3). 4th World Parkinson Congress (WPC). Portland, OR. September 20 – 23, 2016.
  • Pahwa R, Tanner C, Hauser R, Howard R, Johnson R, Stempien MJ. ADS-5102 (amantadine HCl) Extended-Release Capsules Improves Activities of Daily Living in Parkinson’s Disease Patients by Reducing Levodopa-Induced Dyskinesia: A Post-Hoc Analysis from the Phase 3 EASE LID Study. 4th World Parkinson Congress (WPC). Portland, OR. September 20 – 23,  2016.
  • Pahwa R, Tanner CM, Hauser RA, Nausieda P, Truong DD, Hull K, Agarwal P, Johnson R, Ruby A, McClure N, Stempien MJ. ADS-5102 (amantadine HCl) Extended-Release Capsules Reduced Levodopa-Induced Dyskinesia (LID) in the Phase 3 EASE LID Study. 68th American Academy of Neurology Annual Meeting (AAN). Vancouver, BC, Canada. April 14-19, 2016.
  • Nguyen J, Brigham E, Oksman J, Ahtoniemi T, Sava B, Buisson B. Amantadine Ameliorates Gait Deficits and Disease Severity in an Animal Model of Multiple Sclerosis. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Barcelona, Spain. October 7-10, 2015.
  • Stempien MJ, Pahwa, R, Tanner CM, Sethi K, Howard RE, Ruby AE, Nguyen J, McClure NL, Hauser RA. (2015). ADS-5102 Increased ON Time Without Troublesome Dyskinesia Throughout Waking Hours in the EASED Study. 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS). San Diego, California, US. June 14-18, 2015.
  • Stempien MJ, Hauser RA, Brady C, Ruby AE, McClure NL, Goetz CG. Rater
    Training and Data Completeness in the Study of ADS-5102 in Levodopa-induced Dyskinesia (EASED Study). 18th International Congress of Parkinson’s Disease and Movement Disorders (MDS). Stockholm, Sweden. June 8-12, 2014.
  • Pahwa R, Tanner CM, Hauser RA, Sethi KD, Isaacson SH, Truong DD, Struck LK, Stempien MJ, McClure N, Went GT. Safety and Efficacy Study of ADS-5102 (Amantadine HCl) Extended Release Capsules in Levodopa-Induced Dyskinesia (EASED Study). American Academy of Neurology (AAN) 66th Annual Meeting. Philadelphia, PA. April 26-May 3, 2014.
  • Pahwa R, Tanner CM, Hauser RA, Sethi KD, Isaacson SH, Truong DD, Struck LK, Stempien MJ, Went GT. Safety and Efficacy Study of ADS-5102 in Levodopa-Induced Dyskinesia (EASED Study). 3rd World Parkinson’s Congress. Montreal, Canada. October 1-4, 2013.
  • Pahwa R, Tanner CM, Hauser RA, Sethi KD, Isaacson SH, Truong DD, Struck LK, Stempien MJ, Went GT. Randomized Trial of Extended Release Amantadine in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia (EASED Study). 17th International Congress of Parkinsons Disease and Movement Disorders (MDS). Sydney, Australia. June 16-20, 2013.
  • Went G. Exploring the potential of modified release aminoadamantanes in Parkinson’s Disease and related indications. Cambridge Healthtech Institute’s 2nd Annual Targeting Parkinson’s Disease Symposium. Philadelphia, PA. June 5-7, 2012.

Preclinical

  • Nguyen JT, Stempien MJ, Went G. Preclinical and clinical update on Nurelin (ADS-5102), a novel formulation of amantadine HCl for CNS disorders. 53rd NCDEU. Hollywood, FL. May 28-31, 2013.
  • Nguyen JT, Wang T, Van K, Went GT, Lyeth BG. Amantadine Improves Cognitive Outcome after Fluid Percussion Traumatic Brain Inujury in Rats. American Academy of Neurology 65th Annual Meeting. San Diego, CA. March 16, 2013.
  • Wang T, Van K, Went G, Nguyen J, Lyeth B. Repeated Post-Injury Dosing with Amantadine Improves Cognitive Outcome after Fluid Percussion TBI in Rats. National Neurotrauma Society. Phoenix, AZ. July 22-25, 2012.